Renovo inks $875M deal for scarring drug

Demonstrating a big appetite for potential blockbusters, Shire has agreed to pay Renovo $75 million up front along with a $50 million equity payment as part of an $875 million deal for the exclusive development and commercialization rights to Juvista, a scarring drug. The deal includes $700 million in scheduled milestone payments. The drug is intended for use after surgery and cosmetic procedures as well as for burn victims. The deal demonstrates a bullish estimate of the potential market for Juvista. Researchers say the drug could garner $4 billion a year in the U.S. market alone. The therapy is in development and could be approved in 2011. The partnership covers countries outside of the EU.

"This is a novel biopharmaceutical drug candidate that we believe could become a leader in the market for prevention and treatment of scarring, a market served by specialist physicians--as are all of Shire's markets," said Shire CEO Matthew Emmens.

- check out the release for more
- here's the report from The Times

Related Articles:
Renovo CEO bullish on partnership prospects. Report
Renovo sees shares jump on first day. Report
Shire snares New River Pharma in $2.6B buyout. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.